|Rat Target Sites||Mouse Target Sites||TD50 (mg/kg/day)|
|mgl per spl sub ubl vsc||bon mgl ubl vsc||vsc||liv vsc||43.6m||840m|
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
o-TOLUIDINE.HCl 636-21-5 6131 M f b6c eat 24m24 TR153 : 0 130.mg 390.mg liv MXA 754.mg * P<.002 c 428.mg 2.86gm 0/20 4/50 13/50 liv:hpa,hpc. liv hpc 1.52gm * P<.02 c 716.mg n.s.s. 0/20 2/50 7/50 TBA MXB 1.35gm * P<.4 344.mg n.s.s. 8/20 19/50 26/50 liv MXB 754.mg * P<.002 428.mg 2.86gm 0/20 4/50 13/50 liv:hpa,hpc,nnd. lun MXB no dre P=1. 1.66gm n.s.s. 1/20 2/50 2/50 lun:a/a,a/c. 6132 M m b6c eat 24m24 TR153 : 0 120.mg 360.mg --- MXA a 926.mg * P<.005 c 453.mg 8.19gm 1/20 2/50 12/50 ---:hem,hes. --- hes a 1.22gm / P<.01 c 554.mg 80.1gm 1/20 1/50 10/50 TBA MXB a no dre P=1. 304.mg n.s.s. 17/20 28/50 30/50 liv MXB a 12.7gm * P<1. 404.mg n.s.s. 5/20 19/50 14/50 liv:hpa,hpc,nnd. lun MXB a no dre P=1. 473.mg n.s.s. 5/20 5/50 (3/50) lun:a/a,a/c. 6133 M f chi eat 68w90 381 : 0 1.09gm 2.50gm Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973 liv mix av 1.65gm * P<.008 - 544.mg 46.2gm 0/15 3/18 2/21 lun mix av no dre P=1. - 1.18gm n.s.s. 8/15 3/18 0/21 tba mix av 699.mg * P<.007 283.mg 12.1gm 11/15 12/18 8/21 6134 M f chi eat 68w90 381 : pool 0 1.09gm 2.50gm --- vsc av 1.24gm * P<.0005 + 513.mg 3.75gm 8/102 4/18 8/21 6135 M m chi eat 68w90 381 : 0 1.01gm 2.30gm --- vsc av 646.mg / P<.0005 + 300.mg 1.75gm 0/14 4/14 8/11 liv mix av 1.40gm * P<.005 - 474.mg 12.0gm 1/14 2/14 4/11 lun mix av 1.16gm * P<.1 - 353.mg n.s.s. 4/14 5/14 2/11 tba mix av 325.mg / P<.0005 154.mg 1.13gm 8/14 10/14 11/11 6136 M m chi eat 68w90 381 : pool 0 1.01gm 2.30gm --- vsc av 660.mg / P<.0005 + 301.mg 1.84gm 5/99 4/14 8/11 6137 R f f34 eat 24m24 TR153 : 0 150.mg 300.mg MXB MXB s 77.9mg / P<.0005 51.9mg 141.mg 7/20 32/50 48/50 mgl:adn,fba; mul:ang,fbs,ost,srn; spl:ang,ost,srn; ubl: tcc,tpp. C mgl fba s 115.mg / P<.0005 c 72.0mg 244.mg 6/20 20/50 35/50 mgl MXA s 119.mg / P<.0005 c 73.4mg 268.mg 7/20 20/50 35/50 mgl:adn,fba. ubl MXA s 175.mg / P<.0005 c 111.mg 299.mg 0/20 10/50 22/50 ubl:tcc,tpp. ubl tcc s 185.mg / P<.0005 c 116.mg 318.mg 0/20 9/50 22/50 mul MXA s 332.mg / P<.0005 c 199.mg 605.mg 0/20 3/50 21/50 mul:ang,fbs,ost,srn. spl MXA s 337.mg * P<.0005 c 193.mg 810.mg 0/20 9/50 12/50 spl:ang,ost,srn. mul ost s 423.mg / P<.0005 c 236.mg 844.mg 0/20 0/50 18/50 spl ang s 450.mg * P<.002 c 239.mg 1.53gm 0/20 7/50 9/50 TBA MXB s 75.8mg * P<.0005 47.1mg 174.mg 13/20 43/50 48/50 liv MXB s no dre P=1. n.s.s. n.s.s. 0/20 2/50 0/50 liv:hpa,hpc,nnd. 6138 R m f34 eat 24m24 TR153 : 0 120.mg 240.mg MXB MXB as 23.3mg / P<.0005 15.5mg 35.3mg 0/20 44/50 48/50 mul:ang,fbs,mso,ost,srn; spl:fib; sub:fib; tnv:mso. C sub fib as 33.3mg / P<.0005 c 20.9mg 54.6mg 0/20 28/50 27/50 mul MXA as 93.2mg / P<.0005 c 59.7mg 140.mg 0/20 15/50 37/50 mul:ang,fbs,ost,srn. MXA mso as 97.4mg * P<.0005 c 53.3mg 189.mg 0/20 17/50 9/50 mul:mso; tnv:mso. spl fib as 134.mg * P<.0005 c 64.1mg 355.mg 0/20 10/50 2/50 mul fbs as 184.mg / P<.0005 c 99.1mg 336.mg 0/20 8/50 20/50 mul srn as 394.mg / P<.0005 c 192.mg 981.mg 0/20 3/50 11/50 TBA MXB as 24.4mg / P<.0005 15.8mg 40.6mg 10/20 50/50 48/50 liv MXB as 645.mg / P<.06 169.mg n.s.s. 1/20 1/50 3/50 liv:hpa,hpc,nnd. 6139 R m f34 eat 72w93 1487 0 124.mg Hecht;clet,16,103-108;1982 ski fib e 38.7mg P<.0005 + 21.8mg 74.2mg 1/27 25/30 mam fba e 149.mg P<.0005 + 74.0mg 372.mg 0/27 11/30 spl fib e 167.mg P<.0005 + 81.0mg 452.mg 0/27 10/30 pec scs e 190.mg P<.0005 89.2mg 571.mg 0/27 9/30 ubl mix e 474.mg P<.03 + 164.mg n.s.s. 0/27 4/30 liv mix e 1.00gm P<.4 212.mg n.s.s. 1/27 3/30 6140 R m cdr eat 64w68 381 : 0 192.mg 384.mg Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973 sub mix v 36.7mg * P<.0005 + 22.4mg 62.5mg 0/16 18/23 21/24 liv mix v 2.96gm * P<.3 - 482.mg n.s.s. 0/16 0/23 1/24 tba mix v 36.1mg * P<.0005 20.2mg 82.4mg 9/16 19/23 23/24 6141 R m cdr eat 64w68 381 : pool 0 192.mg 384.mg sub mix v 38.8mg * P<.0005 + 23.6mg 65.9mg 18/111 18/23 21/24 ubl mix v 131.mg * P<.0005 + 48.9mg 535.mg 5/111 3/23 4/24
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.